tailieunhanh - Báo cáo y học: "A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. | Available online http content 13 2 R36 Research A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor tifacogin in patients with severe community-acquired pneumonia Pierre-Franọois Laterre1 Steven M Opal2 Edward Abraham3 Steven P LaRosa2 Abla A Creasey4 Fang Xie5 Lona Poole5 and Richard G Wunderink6 1st Luc University Hospital Université Catholique de Louvain Avenue Hippocrate 10 1200 Brussels Belgium 2Division of Infectious Diseases Rhode Island Hospital POB Suite 330 593 Eddy Street Providence RI 02903 USA 3Department of Medicine University of Alabama at Birmingham School of Medicine 420 Boshell Building 1808 7th Avenue South Birmingham AL 35294 USA 4Alza Corporation Johnson Johnson 1 900 Charleston Road Mountain View CA 94042 USA 5Novartis 4560 Horton Street Emeryville CA 94608 USA 6Division of Pulmonary and Critical Care Medicine Northwestern University Feinberg School of Medicine 240 E. Huron Street McGaw M300 Chicago IL 60611 USA Corresponding author Pierre-Franọois Laterre laterre@ Received 8 Feb 2008 Revisions requested 14 Mar 2008 Revisions received 22 Oct 2008 Accepted 15 Mar 2009 Published 15 Mar 2009 Critical Care 2009 13 R36 doi cc7747 This article is online at http content 13 2 R36 2009 Laterre et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction The purpose of this analysis was to determine the potential efficacy of recombinant human tissue factor pathway inhibitor tifacogin in a subpopulation of patients with community-acquired pneumonia CAP from a phase III study of severe sepsis. Methods A retrospective review of patients with suspected pneumonia was conducted by an independent .